- Cellipont Bioservices has entered a strategic collaboration with Ronawk to improve the scalable expansion of mesenchymal stem cells using the Bio-OS platform.
- The partnership aims to enhance quality, consistency, and efficiency in MSC manufacturing for biologics and regenerative medicine.
Cellipont Bioservices has announced a strategic collaboration with Ronawk to accelerate the scalable expansion of mesenchymal stem cells (MSCs). The partnership combines Cellipont’s cGMP manufacturing and process development capabilities with Ronawk’s Bio-OS technology, which recreates the natural cellular microenvironment.
The collaboration aims to address challenges in MSC production, including scalability, consistency, capital efficiency, and readiness for therapeutic applications.
“Cellipont is committed to enabling the next generation of cell therapies. Integrating Ronawk’s platform would support scalable and cost-effective manufacturing.”
Darren Head, CEO of Cellipont Bioservices
Ronawk said MSC expansion at scale while maintaining quality and potency has been a long-standing hurdle in regenerative medicine. The company stated that combining its platform with Cellipont’s expertise would enable higher-quality cell production. MSCs are recognised for their regenerative and immunomodulatory properties and are widely studied in clinical research.
The collaboration is intended to provide improved pathways for large-scale, consistent MSC manufacturing across biologics, exosome therapeutics, and regenerative medicine, supporting broader therapeutic development across the biotech sector.
